Invasive community-associated MRSA infections: epidemiology and antimicrobial management

被引:21
|
作者
Pichereau, Solen [1 ,2 ,3 ]
Rose, Warren E. [1 ]
机构
[1] Univ Madison, Sch Pharm, Pharm Practice Div, Madison, WI 53705 USA
[2] INSERM, ERI 23, F-75654 Paris 13, France
[3] Univ Poitiers, Poitiers, France
关键词
CA-MRSA; epidemiology; resistance; Staphylococcus aureus; treatment; RESISTANT STAPHYLOCOCCUS-AUREUS; SKIN-STRUCTURE INFECTIONS; SOFT-TISSUE INFECTIONS; BLOOD-STREAM INFECTIONS; IN-VITRO ACTIVITY; INDUCIBLE CLINDAMYCIN RESISTANCE; VENTILATOR-ASSOCIATED PNEUMONIA; GRAM-POSITIVE COCCI; DOUBLE-BLIND; METHICILLIN-RESISTANT;
D O I
10.1517/14656566.2010.511614
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Importance of the field: Community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) is now a predominant cause of infections in the community and is adding to the overwhelming MRSA burden in the hospital setting. CA-MRSA is most commonly noted as a prominent pathogen in skin and soft tissue infections (SSTI) but has been increasingly described in more invasive disease. New developments in the epidemiology and treatment of CA-MRSA have emerged to improve the understanding of this disease. Areas covered in this review: We present the latest epidemiologic and clinical treatment studies of CA-MRSA in a variety of infection types. The methods used involve a comprehensive literature search of the previous 10 years, including a detailed focus on new literature in the last 5 years. The search terms used were 'CA-MRSA epidemiology', 'S. aureus resistance', 'CA-MRSA treatment', and 'S. aureus virulence'. What the reader will gain: An in-depth understanding of the changing epidemiology of CA-MRSA and management of SSTI and more invasive infections with this pathogen. Adjunctive and alternative therapies are also reviewed. Take home message: The epidemiology of CA-MRSA is rapidly evolving. Increasing multi-drug resistance along with virulence factors associated with this serious disease complicate its treatment. Additional clinical trials are needed to select optimal regimens in the treatment of invasive CA-MRSA infections.
引用
收藏
页码:3009 / 3025
页数:17
相关论文
共 50 条
  • [21] Community-associated MRSA as a new nosocomial pathogen
    Chung, Doo-Ryeon
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2017, 50 : S12 - S12
  • [23] Community-associated MRSA displaying glycopeptide heteroresistance
    Huang, V
    Dabaja, GS
    Rybak, MJ
    PHARMACOTHERAPY, 2004, 24 (10): : 1444 - 1444
  • [24] Response: Re: Trimethoprim-sulfamethoxazole or Clindamycin for Community-Associated MRSA (CA-MRSA) Skin Infections
    Frei, Christopher R.
    Miller, Monica L.
    Forcade, Nicolas A.
    JOURNAL OF THE AMERICAN BOARD OF FAMILY MEDICINE, 2011, 24 (03) : 332 - 333
  • [25] Replacement of healthcare-associated MRSA by community-associated MRSA in Queensland: Confirmation by genotyping
    Nimmo, Graeme R.
    Bergh, Haakon
    Nakos, Jennifer
    Whiley, David
    Marquess, John
    Huygens, Flavia
    Paterson, David L.
    JOURNAL OF INFECTION, 2013, 67 (05) : 439 - 447
  • [26] Community-Associated MRSA: New Guidelines for a New Age
    Holcomb, Susan Simmons
    NURSE PRACTITIONER, 2006, 31 (09): : 8 - 12
  • [27] Glycopeptide and daptomycin resistance in community-associated MRSA in the UK
    A. Kirby
    C. Edwards
    C. M. Broughton
    N. J. Williams
    Infection, 2011, 39 : 277 - 279
  • [28] Glycopeptide and daptomycin resistance in community-associated MRSA in the UK
    Kirby, A.
    Edwards, C.
    Broughton, C. M.
    Williams, N. J.
    INFECTION, 2011, 39 (03) : 277 - 279
  • [29] Illicit drug use and community-associated MRSA bacteremia
    Kreisel, K.
    Johnson, J.
    Shardell, M.
    Perencevich, E.
    Stine, O.
    Roghmann, M.
    AMERICAN JOURNAL OF EPIDEMIOLOGY, 2008, 167 (11) : S74 - S74
  • [30] Community-Associated MRSA Coming to a Patient Near You?
    Mendyk, Michelle K.
    NURSE PRACTITIONER, 2008, 33 (03): : 26 - 32